Sola Security Launches Lumina, an Autonomous Security Deep Research Platform for Actionable Risk Intelligence Gracell Biotechnologies to Participate in Upcoming Virtual Investor Conferences in September
SUZHOU, China and PALO ALTO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc….
Rakovina Therapeutics Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, Aug. 26, 2021 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV), a…
Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights
– Company continues to increase R&D activities to advance clinical and preclinical programs – – Second…
Balstilimab Monotherapy Data Published in Gynecologic Oncology
Objective response rate of 20% and median duration of response not reached with 14.6 month…
SOPHiA GENETICS to Report Second Quarter 2021 Financial Results on September 9, 2021
BOSTON and LAUSANNE, Switzerland, Aug. 26, 2021 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH)…
Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia
On average, pediatric congenital athymia patients spent 150.6 days each year in the hospital with…
ABVC BioPharma Provides Vitargus® Update
FREMONT, CA, Aug. 26, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…
Shockwave Medical to Participate in Two Upcoming Virtual Investor Conferences
SANTA CLARA, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a…
GoodRx to Present Virtually at Upcoming Investor Conferences
SANTA MONICA, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — GoodRx Holdings Inc. (Nasdaq: GDRX), America’s…
Nuvectis Pharma Raises $15 Million and In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor from the CRT Pioneer Fund
NXP800 is a novel, oral, small molecule heat shock factor 1 (HSF1) pathway inhibitor discovered…
Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary
Developing a new era of precision medicines using a unique and proprietary drug discovery platform DURHAM,…
Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections
CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company…
President and CEO of Rafael Pharmaceuticals, Sanjeev Luther, to Present at the 11th Annual World Orphan Drug Congress USA 2021
CRANBURY, N.J., Aug. 26, 2021 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”),…
Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV
CRISPR-based therapies as a curative approach to HIV infection included in the program for first…
Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in its Long-Acting Next Generation Psychedelic Compounds
TORONTO, Aug. 26, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB:…
Zogenix Receives Orphan Drug Designation for FINTEPLA® (Fenfluramine) in Japan
Zogenix plans to submit a new drug application (J-NDA) for FINTEPLA in Japan for the…
Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates
– Established three clinical collaborations with Merck to conduct global combination trials with pembrolizumab for three…
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
Name change underscores the Company’s transition to developing innovative targeted therapies in immunology, immuno-oncology, and…
BioCryst Appoints Dr. Steven Galson to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today…
Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine
BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage…